Hydrochlorothiazide/ Olmesartan Medoxomil Aurobindo (Olmesartan Medoxomil, Hydrochlorothiazide)

Hydrochlorothiazide/Olmesartan Medoxomil Aurobindo is indicated for the treatment of hypertension, particularly when monotherapy does not achieve target blood pressure.

• As initial therapy for patients requiring combined antihypertensive effect.
• In patients already on separate olmesartan and hydrochlorothiazide who need a simplified regimen.
• For individuals with salt‑sensitive hypertension where diuretic action adds benefit.
• In cases where blood pressure control has been suboptimal with either component alone.
• As part of a comprehensive cardiovascular risk‑reduction plan including lifestyle modification.

• Olmesartan medoxomil selectively blocks angiotensin II type 1 (AT₁) receptors, preventing angiotensin II‑mediated vasoconstriction and aldosterone secretion, which lowers systemic vascular resistance. Hydrochlorothiazide acts on the distal convoluted tubule to inhibit the Na⁺/Cl⁻ cotransporter, reducing sodium and water reabsorption, thereby decreasing plasma volume. Together they address two major contributors to elevated arterial pressure.

Like all antihypertensive agents, the combination may cause adverse reactions; the frequency and severity can vary among individuals.

Common

• Dizziness or light‑headedness, especially after the first dose.
• Increased urination or mild electrolyte changes such as low potassium.
• Headache.
• Fatigue or weakness.

Serious

• Severe dehydration or electrolyte imbalance (e.g., hyponatremia, hypokalemia).
• Acute kidney injury or significant rise in serum creatinine.
• Allergic reactions including rash, angioedema, or anaphylaxis.

Healthcare providers should evaluate patient history and laboratory values before prescribing Hydrochlorothiazide/Olmesartan Medoxomil Aurobindo.

• Assess renal function; avoid use in severe renal impairment.
• Monitor electrolytes, particularly potassium and sodium, during therapy.
• Use caution in patients with a history of gout, as thiazides may increase uric acid.
• Evaluate for hepatic disease, as olmesartan is metabolized in the liver.
• Consider pregnancy status; the safety profile in pregnancy is not established.
• Review concomitant use of other antihypertensives to prevent excessive blood‑pressure reduction.
• Advise patients to rise slowly from sitting or lying positions to reduce orthostatic dizziness.

The fixed‑dose combination can interact with several medicines; awareness of these interactions helps prevent adverse outcomes.

Avoid

• Concurrent use with other potent diuretics or potassium‑sparing agents, which may cause severe electrolyte disturbances.
• Co‑administration with aliskiren in patients with diabetes or renal impairment.
• Use with strong CYP3A4 inhibitors (e.g., ketoconazole) that may increase olmesartan levels.

Use with caution

• NSAIDs, which can blunt antihypertensive effect and affect renal function.
• Lithium, as thiazides may raise lithium concentrations.
• ACE inhibitors or other ARBs, increasing risk of hyperkalemia and renal impairment.
• Beta‑blockers, which may enhance blood‑pressure lowering.